Table 1 Univariate cox regression analysis of patient and COVID-19 characteristics on OS and DFS.
Characteristic | Overall survival | Disease-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
N | HR | 95% CI | p-value | N | HR | 95% CI | p-value | |
Year of Transplantation | 49 | 49 | ||||||
2020 | — | — | — | — | ||||
2021 | 0.31 | 0.08, 1.15 | 0.080 | 0.38 | 0.11, 1.29 | 0.12 | ||
2022 | 0.00 | 0.00, Inf | >0.9 | 0.00 | 0.00, Inf | >0.9 | ||
Disease Status at HSCT | 38 | 38 | ||||||
CR | — | — | — | — | ||||
no CR | 2.97 | 0.54, 16.2 | 0.2 | 0.79 | 0.14, 4.30 | 0.8 | ||
Karnofsky Index | 48 | 48 | ||||||
<90 | — | — | — | — | ||||
90–100 | 0.55 | 0.15, 2.07 | 0.4 | 0.23 | 0.07, 0.78 | 0.019 | ||
Patient Age at HSCT (years) | 49 | 1.01 | 0.97, 1.06 | 0.6 | 49 | 0.98 | 0.94, 1.02 | 0.3 |
Patient Sex | 49 | 49 | ||||||
Female | — | — | — | — | ||||
Male | 0.92 | 0.25, 3.45 | >0.9 | 0.63 | 0.19, 2.09 | 0.5 | ||
Donor Sex | 46 | 46 | ||||||
Female | — | — | — | — | ||||
Male | 0.31 | 0.08, 1.14 | 0.079 | 0.55 | 0.17, 1.83 | 0.3 | ||
Donor Type | 49 | 49 | ||||||
Haplo | — | — | — | — | ||||
MMUD | 0.88 | 0.12, 6.25 | 0.9 | 1.14 | 0.23, 5.68 | 0.9 | ||
MRD | 0.36 | 0.03, 3.97 | 0.4 | 0.26 | 0.03, 2.46 | 0.2 | ||
MUD | 0.75 | 0.14, 4.12 | 0.7 | 0.58 | 0.13, 2.64 | 0.5 | ||
CMV Antibody Match | 49 | 49 | ||||||
Match | — | — | — | — | ||||
IgG negative donor, positive patient | 2.61 | 0.62, 10.9 | 0.2 | 1.50 | 0.40, 5.67 | 0.5 | ||
IgG positive donor, negative patient | 0.96 | 0.11, 8.27 | >0.9 | 0.00 | 0.00, Inf | >0.9 | ||
Karyotyp | 41 | 41 | ||||||
Abnormal | — | — | — | — | ||||
Normal | 0.79 | 0.14, 4.34 | 0.8 | 0.54 | 0.11, 2.71 | 0.5 | ||
Conditioning | 41 | 41 | ||||||
MAC | — | — | — | — | ||||
RIC/NMA | 2.17 | 0.44, 10.8 | 0.3 | 1.05 | 0.19, 5.77 | >0.9 | ||
Maximal Severity of COVID-19 (WHO) | 49 | 49 | ||||||
Mild | — | — | — | — | ||||
Moderate | 4.90 | 0.69, 34.9 | 0.11 | 1.36 | 0.25, 7.41 | 0.7 | ||
Severe/critical | 7.20 | 1.39, 37.2 | 0.019 | 1.99 | 0.53, 7.52 | 0.3 | ||
Time from Neoplasia to COVID-19 (days) | 39 | 1.00 | 1.00, 1.00 | >0.9 | 39 | 1.00 | 1.00, 1.00 | 0.10 |
Time from COVID-19 to HSCT (days) | 48 | 1.00 | 0.99, 1.01 | >0.9 | 48 | 1.00 | 0.99, 1.01 | 0.7 |
CT-abnormalities | 49 | 49 | ||||||
No pneumonia | — | — | — | — | ||||
Pneumonia like changes | 3.49 | 0.44, 27.9 | 0.2 | 2.11 | 0.46, 9.76 | 0.3 | ||
FEV1 (%) prior to Allo | 32 | 0.97 | 0.91, 1.05 | 0.5 | 32 | 0.98 | 0.93, 1.04 | 0.6 |
FEV1/FVC (%) | 39 | 1.01 | 1.00, 1.03 | 0.049 | 39 | 1.01 | 1.00, 1.03 | 0.028 |
DLCO (%) prior to Allo | 29 | 0.92 | 0.85, 1.00 | 0.056 | 29 | 0.98 | 0.93, 1.03 | 0.4 |
ICU during COVID19 | 46 | 46 | ||||||
No | — | — | — | — | ||||
Yes | 2.12 | 0.51, 8.89 | 0.3 | 1.74 | 0.43, 7.02 | 0.4 | ||
GvHD Prophylaxis | 36 | 36 | ||||||
ATG-based | — | — | — | — | ||||
CsA-based | 2.65 | 0.44, 15.9 | 0.3 | 2.12 | 0.43, 10.5 | 0.4 | ||
postCy-based | 2.44 | 0.34, 17.4 | 0.4 | 2.40 | 0.46, 12.4 | 0.3 | ||
Peak CRP during COVID19 (mg/dl) | 26 | 1.00 | 0.90, 1.11 | >0.9 | 26 | 1.02 | 0.92, 1.12 | 0.7 |
Peak IL6 during COVID19 (ng/l) | 14 | 1.00 | 1.00, 1.00 | 0.094 | 14 | 1.00 | 1.00, 1.00 | 0.10 |
Peak PCT during COVID19 (ng/ml) | 13 | 0.02 | 0.00, 24.3 | 0.3 | 13 | 0.00 | 0.00, 67.1 | 0.3 |
